ISCO (International Stem Cell) Stock Based Compensation: $0.25 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISCO International Stem Cell Corp ISCO
28 GF Score
Price $0.28
GF Value $0.13
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is International Stem Cell Stock Based Compensation?

International Stem Cell ISCO +62.32% 28 Stock Based Compensation is $0.25 Mil as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 28/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 5 warning signs investors should review.

International Stem Cell's Stock Based Compensation for the three months ended in Mar. 2026 was $0.06 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25 Mil.

International Stem Cell Stock Based Compensation Related Terms

International Stem Cell Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for International Stem Cell's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Stock Based Compensation Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.40 0.46 0.47 0.29

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.06 0.06 0.06 0.06
ISCO
28GF Score
International Stem Cell Corp ISCO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25 Mil.

What does a Stock Based Compensation of $0.25 Mil mean?
International Stem Cell (ISCO) has a Stock Based Compensation of $0.25 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for International Stem Cell and its competitors.
Is International Stem Cell's Stock Based Compensation too high?
International Stem Cell's current Stock Based Compensation is $0.25 Mil. Overall, International Stem Cell has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Stock Based Compensation compare to ZVSA and AXIM?
International Stem Cell's Stock Based Compensation of $0.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for International Stem Cell and its competitors. International Stem Cell's current Stock Based Compensation is $0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.28 — trading 115.4% above its estimated fair value. The current Stock Based Compensation is $0.25 Mil. International Stem Cell's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Stock Based Compensation is $0.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.28 is trading 115.4% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Stock Based Compensation: $0.25 Mil
  • GF Value™: $0.13 vs. price of $0.28 (115.4% above fair value)
  • GF Score™: 28/100 with 5 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
28GF Score

Get the complete analysis for ISCO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price
$0.13
GF Value